RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Voyager Therapeutics Stock

Voyager Therapeutics Liabilities 2024

Voyager Therapeutics Liabilities

114.96 M USD

Ticker

VYGR

ISIN

US92915B1061

WKN

A143XJ

In 2024, Voyager Therapeutics's total liabilities amounted to 114.96 M USD, a 14.62% difference from the 100.3 M USD total liabilities in the previous year.

Voyager Therapeutics Aktienanalyse

What does Voyager Therapeutics do?

Voyager Therapeutics Inc is a biopharmaceutical company specializing in the development of gene therapy products. The company was founded in 2013 in Cambridge, Massachusetts. The main business model of Voyager Therapeutics involves the development, manufacturing, and marketing of gene therapy products. The company specializes in nervous system and ocular therapies and works closely with leading scientists and clinical institutes. Voyager Therapeutics has several business and research divisions: the Parkinson's Disease division, the Huntington's Disease division, and the Amyotrophic Lateral Sclerosis (ALS) division. The Parkinson's Disease division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Parkinson's disease. The products being developed in this division aim to increase the amount of dopamine in the brain to alleviate the symptoms of Parkinson's disease. Parkinson's patients often suffer from symptoms such as tremors, stiffness, and lack of movement. The Huntington's Disease division of Voyager Therapeutics specializes in developing gene therapy products for the treatment of Huntington's disease. This disease is a hereditary condition that leads to the accumulation of toxic proteins in the brain, eventually causing neurological symptoms such as slow thinking and tremors. The ALS division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is a neurodegenerative disease in which nerve cells in the brain and spinal cord degenerate, leading to muscle weakness and atrophy. Voyager Therapeutics works closely with various institutions and companies to advance its research and development. Key collaboration partners include Sanofi Genzyme, Abbvie, Neurocrine Biosciences, and the University of Massachusetts Medical School. Some of Voyager Therapeutics' key products are currently in clinical trials or in development. The company is working on developing gene therapies for the treatment of Parkinson's disease, Huntington's disease, and ALS. One example of a product developed by Voyager Therapeutics is VY-AADC, a gene therapy for the treatment of Parkinson's disease. It is currently being tested in Phase 2 clinical trials. Another example is VY-HTT01, a gene therapy for the treatment of Huntington's disease. VY-HTT01 is currently in the preclinical development phase and is expected to be tested in clinical trials in the coming years. Overall, Voyager Therapeutics has a promising future in the gene therapy industry. The company has already achieved significant successes and continues to work intensively on developing new therapies to help people with neurological disorders. Voyager Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Voyager Therapeutics's Liabilities

Voyager Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Voyager Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Voyager Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Voyager Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Voyager Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Voyager Therapeutics stock

What is the level of liabilities of Voyager Therapeutics this year?

Voyager Therapeutics has a debt balance of 114.96 M USD this year.

What were the liabilities of Voyager Therapeutics compared to the previous year?

The liabilities of Voyager Therapeutics have increased by 14.62% increased compared to the previous year.

What are the consequences of high debt for investors of Voyager Therapeutics?

High liabilities can pose a risk for investors of Voyager Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Voyager Therapeutics?

Low liabilities mean that Voyager Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Voyager Therapeutics affect the company?

An increase in liabilities of Voyager Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Voyager Therapeutics affect the company?

A decrease in the liabilities of Voyager Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Voyager Therapeutics?

Some factors that can influence the liabilities of Voyager Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Voyager Therapeutics so important for investors?

The liabilities of Voyager Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Voyager Therapeutics take to modify the liabilities?

To change its liabilities, Voyager Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Voyager Therapeutics pay?

Over the past 12 months, Voyager Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Voyager Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Voyager Therapeutics?

The current dividend yield of Voyager Therapeutics is .

When does Voyager Therapeutics pay dividends?

Voyager Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Voyager Therapeutics?

Voyager Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Voyager Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Voyager Therapeutics located?

Voyager Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Voyager Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Voyager Therapeutics from 7/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/17/2024.

When did Voyager Therapeutics pay the last dividend?

The last dividend was paid out on 7/17/2024.

What was the dividend of Voyager Therapeutics in the year 2023?

In the year 2023, Voyager Therapeutics distributed 0 USD as dividends.

In which currency does Voyager Therapeutics pay out the dividend?

The dividends of Voyager Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Voyager Therapeutics

Our stock analysis for Voyager Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Voyager Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.